Amgen Inc.

Scott Michael Silbiger

Raymond A Koski

Richard Yeh

Gary Elliott

Giorgio Senaldi

Shuqian Jing

Lars Eyde Theill

Eugene Medlock

Gang Yu

Hung Q Nguyen

Hung Q Nquyen

Gary S Elliot

The present invention relates in general to metalloproteinase inhibitors and to polynucleotides encoding such inhibitors. In particular, the invention relates to novel mammalian inhibitors of metalloproteinase, which are designated as type three or TIMP-3, to fragments, derivatives, and analogs thereof, and to polynucleotides encoding the same. Novel methods of producing such compositions and novel methods of using such compositions are also provided.

Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods

The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.

IL-receptor like molecules and uses thereof

Novel MK61 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing MK61 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with MK61 polypeptides.

Antibody to TNF receptor-like molecules

Nucleic acids encoding MK61 receptors

IL-17 receptor like molecules and uses thereof

The present invention reveals a class of novel inhibitors of metalloproteinase. For convenience, these polypeptides are referred to as &ldquo;TIMP-3&rdquo;, as these polypeptides represent a new class of members of the tissue inhibitors of metalloproteinases. Also provided are DNA sequences coding for all or part of the TIMP-3s, vectors containing such DNA sequences, and host cells transformed or transfected with such vectors. In addition, methods of producing recombinant TIMP-3s, methods of treating disorders, pharmaceutical compositions including TIMP-3s and antibodies selectively binding TIMP-3s are provided.

Growing community of inventors

Woodland Hills, CA, United States of America

Scott Michael Silbiger